CODX Share Price Performance
US$0.26
-0.79 (-75.55%)
95.3% undervalued intrinsic discount
US$5.50
Fair Value
Price US$0.26
AnalystConsensusTarget US$5.50
Fair ValueUS$5.50
Share PriceUS$0.26
95.3% undervalued intrinsic discount
CODX Community Narratives
AN
Fair Value US$5.50 95.3% undervalued intrinsic discount
Clinical Advancements And Cloud Integration Will Shape Molecular Diagnostics
0users have liked this narrative
1users have commented on this narrative
4users have followed this narrative
CODX Community Fair Values
- US$5.50FV95.3% undervalued intrinsic discount186.13%Revenue growth p.a.0users have liked this narrative1users have commented on this narrative4users have followed this narrative12 days ago author updated this narrative
Recent CODX News & Updates
No updates
Co-Diagnostics, Inc. Key Details
Last Reported Earnings
Mar 31, 2025
Next Reporting Earnings
Aug 14, 2025
- Earnings per share (EPS)
- -1.06
- Gross Margin
- 77.52%
- Net Profit Margin
- -1,025.29%
- Debt/Equity Ratio
- 0%
Co-Diagnostics, Inc. Competitors
About CODX
- Founded
- 2013
- Employees
- 132
- CEO
- WebsiteView website
Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is based in Salt Lake City, Utah.
U.S. Market Performance
- 7 Days: -2.7%
- 3 Months: 11.4%
- 1 Year: 20.5%
- Year to Date: 5.9%
Over the last 7 days, the market has dropped 2.7%, driven by a decline of 2.4% in the Information Technology sector. As for the longer term, the market has actually risen by 20% in the last year. Looking forward, earnings are forecast to grow by 15% annually. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading